A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

CAR T-cell product quality and stemness (T(stem)) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete T(stem), affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickinson, Michael J., Barba, Pere, Jäger, Ulrich, Shah, Nirav N., Blaise, Didier, Briones, Javier, Shune, Leyla, Boissel, Nicolas, Bondanza, Attilio, Mariconti, Luisa, Marchal, Anne-Laure, Quinn, David S., Yang, Jennifer, Price, Andrew, Sohoni, Akash, Treanor, Louise M., Orlando, Elena J., Mataraza, Jennifer, Davis, Jaclyn, Lu, Darlene, Zhu, Xu, Engels, Boris, Moutouh-de Parseval, Laure, Brogdon, Jennifer L., Moschetta, Michele, Flinn, Ian W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481129/
https://www.ncbi.nlm.nih.gov/pubmed/37249512
http://dx.doi.org/10.1158/2159-8290.CD-22-1276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481129/
https://www.ncbi.nlm.nih.gov/pubmed/37249512
http://dx.doi.org/10.1158/2159-8290.CD-22-1276

Ejemplares similares